Published in J Clin Oncol on October 01, 1983
T-HELPER: automated support for community-based clinical research. Proc Annu Symp Comput Appl Med Care (1992) 2.98
Clinical trial performance of community- vs university-based practices in the submacular surgery trials (SST): SST report no. 2. Arch Ophthalmol (2004) 0.96
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (1985) 4.98
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem (1988) 2.15
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev (1975) 2.10
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med (1973) 2.01
Hormonal risk factors in testicular cancer. A case-control study. Am J Epidemiol (1986) 1.97
Development of the human gastrointestinal tract. A review. Gastroenterology (1976) 1.93
Ferritin and the response to oxidative stress. Biochem J (2001) 1.88
Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med (1973) 1.87
A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol (1996) 1.69
Adriamycin-a review. J Natl Cancer Inst (1975) 1.68
Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol (1985) 1.65
Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem (1995) 1.61
Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A (1990) 1.59
Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol (2000) 1.58
Perceptual-motor behaviour in relation to blood phenobarbitone level: a preliminary report. Dev Med Child Neurol (1968) 1.46
Response of hormone refractory prostate cancer to lycopene. J Urol (2001) 1.40
Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc Natl Acad Sci U S A (1991) 1.36
Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest (1993) 1.36
Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol (1988) 1.35
Bladder cancer, 1996. CA Cancer J Clin (1996) 1.32
The chemotherapy of urologic cancer. Cancer (1975) 1.32
Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev (1976) 1.31
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol (1972) 1.24
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res (1975) 1.22
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
The biology and treatment of superficial bladder cancer. J Clin Oncol (1984) 1.18
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clin Trials (1980) 1.16
Recombinant ferritin: modulation of subunit stoichiometry in bacterial expression systems. Protein Eng (1997) 1.13
Management of locally advanced and disseminated breast cancer. Lancet (1981) 1.13
Interleukin 1 induces ferritin heavy chain in human muscle cells. Biochem Biophys Res Commun (1990) 1.12
Surgery plus adjuvant chemotherapy--a review of therapeutic implications. I. Breast cancer. Cancer Chemother Pharmacol (1980) 1.11
Brain metastases from transitional cell carcinoma of the bladder. J Urol (1988) 1.10
A review of chemotherapy in gastric cancer. Cancer (1974) 1.09
An overview of the 1978 international meeting on comparative therapeutic trials. Biomedicine (1978) 1.08
FER-1, an enhancer of the ferritin H gene and a target of E1A-mediated transcriptional repression. Mol Cell Biol (1995) 1.08
Role of H and L subunits in mouse ferritin. J Biol Chem (1996) 1.07
Tumor necrosis factor-alpha and interleukin 1-alpha regulate transferrin receptor in human diploid fibroblasts. Relationship to the induction of ferritin heavy chain. J Biol Chem (1991) 1.06
Single and combination nonhormonal chemotherapy in breast cancer. Cancer (1972) 1.06
Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02
Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res (1993) 1.02
Glutamine antagonists in chemotherapy. Adv Pharmacol Chemother (1970) 1.01
Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer (1976) 1.00
Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol (1983) 0.99
Management of trials in the development of cancer chemotherapy. Br J Cancer (1978) 0.99
Calibrated phase II clinical trials in oncology. Stat Med (1987) 0.99
p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis (2001) 0.98
Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev (1974) 0.98
Evidence for two mechanisms by which tumor necrosis factor kills cells. J Biol Chem (1989) 0.98
5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. Eur J Cancer (1972) 0.97
Nafoxidine--an antiestrogen for the treatment of breast cancer. Cancer (1976) 0.96
Another case of lycanthropy. Am J Psychiatry (1978) 0.96
Serum markers in germ cell neoplasms. Hematol Oncol Clin North Am (1991) 0.95
Tumor cell cytotoxicity of a novel metal chelator. Blood (1998) 0.95
Iron and ferritin in inflammation and cancer. Adv Inorg Biochem (1994) 0.95
Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants. J Cell Biochem (1993) 0.94
Preferential repression of the H subunit of ferritin by adenovirus E1A in NIH-3T3 mouse fibroblasts. J Biol Chem (1993) 0.94
Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst (1976) 0.94
Obesity, non-protein-bound estradiol levels, and distribution of estradiol in the sera of breast cancer patients. Cancer (1986) 0.93
Extralymphatic Hodgkin's disease. Prognosis and response to therapy. Am J Med (1981) 0.93
Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92
Human H-kininogen is a ferritin-binding protein. J Biol Chem (1998) 0.92
Combination chemotherapy of advanced Hodgkin's disease. A review. Cancer (1974) 0.91
Transcriptional regulation of the mouse ferritin H gene. Involvement of p300/CBP adaptor proteins in FER-1 enhancer activity. J Biol Chem (1999) 0.91
Adenovirus E1A blocks oxidant-dependent ferritin induction and sensitizes cells to pro-oxidant cytotoxicity. FEBS Lett (1999) 0.91
Activation of the ferritin H enhancer, FER-1, by the cooperative action of members of the AP1 and Sp1 transcription factor families. J Biol Chem (1998) 0.91
Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol (1987) 0.89
Streptozotocin and metastatic insulinoma. Ann Intern Med (1971) 0.89
The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study. J Urol (1985) 0.88
The nitrosoureas--thoughts for the future. Cancer Treat Rep (1976) 0.88
Investigational drugs under study by the United States National Cancer Institute. Cancer Treat Rev (1976) 0.88
Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol (1993) 0.88
An overview of the status of the nitrosoureas in other tumors. Cancer Chemother Rep 3 (1973) 0.87
The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87
Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol (1992) 0.86
Antiestrogens in the treatment of breast cancer. Cancer Treat Rev (1976) 0.86
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck. Cancer Treat Rev (1975) 0.86
Augmentation by IL-1 alpha of tumor necrosis factor-alpha cytotoxicity in cells transfected with adenovirus E1A. J Immunol (1993) 0.86
Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy. Cancer (1987) 0.86
The California breast cancer law and government-mandated patient education. CA Cancer J Clin (1982) 0.86
The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. Cancer Treat Rev (1977) 0.86
Clinical comparison of the nitrosoureas. Cancer (1975) 0.86
Regulation of NF-kappaB and HIV-1 LTR activity in mouse L cells by ultraviolet radiation: LTR trans-activation in a nonirradiated genome in heterokaryons. Exp Cell Res (1997) 0.86
Efficient scheduling of cystoscopies in monitoring for recurrent bladder cancer. Med Decis Making (1989) 0.86
Population-based study of small-cell lung cancer. J Clin Oncol (1985) 0.86
Perspectives on research in gynecologic oncology. Cancer (1976) 0.86
Hexamethylmelamine--a new drug with activity in solid tumors. Eur J Cancer (1973) 0.85
Cancer chemotherapy: new developments and changing concepts. Drugs (1980) 0.85
Tumor necrosis factor-induced c-myc expression in the absence of mitogenesis is associated with inhibition of adipocyte differentiation. Proc Natl Acad Sci U S A (1993) 0.85
Radio frequency ablation of lung metastases from renal cell carcinoma. J Urol (2001) 0.84
Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. Cancer (1985) 0.84
Primary osteogenic sarcoma of the bladder. Case report and review of the literature. Cancer (1986) 0.84